Akzo Nobel to sell Organon

Liming, Keith Tan; Ovrebekk, Hilde
March 2007
ICIS Chemical Business Americas;3/19/2007, Vol. 271 Issue 11, p14
Trade Publication
The article discusses the plan of Akzo Nobel to sell its stake in Organon BioSciences (OBS) to pharmaceutical group Schering-Plough. The deal, which is estimated at $14.5 billion, is expected to be closed in the second quarter of 2007. The deal increases the price of Akzo stock by 16 percent. Akzo will use the sales proceeds to expand its coatings and chemicals businesses and reduce its pension liabilities.


Related Articles

  • Akzo sells OBS to US group. Gibson, Jane // ICIS Chemical Business;3/19/2007, Vol. 2 Issue 58, p4 

    The article reports that Akzo Nobel is to sell its Organon BioSciences (OBS) business to U.S. pharmaceutical group Schering-Plough and has dropped plans to issue an initial public offering (IPO). Analysts said that the sale was higher than expected with UBS claiming that it was € 3.2...

  • …but it won't rush into purchases. Jagger, Anna // ICIS Chemical Business;6/18/2007, Vol. 2 Issue 71, p44 

    The article reports on the decision of Akzo Nobel not to rush into purchases following its divestment of Organon BioSciences (OBS), according to CEO Hans Wijers. Wijers states that potential acquisition targets would need to fit strategically with the existing portfolio and create value for...

  • Schering-Plough acquires Intervet.  // Veterinary Record: Journal of the British Veterinary Association;3/31/2007, Vol. 160 Issue 13, p421 

    The article reports that American drug company Schering-Plough has acquired Organon Biosciences, a subsidiary of Dutch firm Akzo Nobel, in March 2007. Organon's products include canine vaccines, dewormers, poultry vaccines and bovine biologicals. Schering's animal health division produces animal...

  • Akzo Nobel/Schering-Plough: good deal all round.  // PharmaWatch: Monthly Review;Apr2007, Vol. 6 Issue 4, p16 

    The article presents information on Akzo Nobel NV selling its healthcare business unit, Organon BioSciences NV, to Schering-Plough Corp. for $14 billion cash. It states that the deal allows Akzo Nobel to conduct acquisitions of its own as well as expansion into non-pharmaceutical markets. It...

  • Akzo's Chemicals Enter a New Era. Young, Ian // Chemical Week;11/1/2006, Vol. 168 Issue 36, p16 

    The article reports on the decision of Azko Nobel to become a manufacturer of chemicals and coatings after the split-off of its pharmaceuticals business Organon BioSciences (OBS) according to Akzo CEO Hans Wijers. It says that the separation of OBS follows after the completion of a major...

  • Schering-Plough to buy Intervet in winning bid for Organon BioSciences.  // DVM: The Newsmagazine of Veterinary Medicine;Apr2007, Vol. 38 Issue 4, p36 

    The article reports on the plan of Schering-Plough Corp. to buy Organon BioSciences NV for $14.4 billion in Kenilworth, New Jersey. This acquisition is said to include Intervet Inc. of Akzo Nobel NV and is expected to close by the end of 2007. Fred Hassan, chairman and chief executive officer...

  • Akzo to Float 20%-30% of Pharma Business in Planned IPO; Shareholders Vote Next Month. Young, Ian // Chemical Week;8/23/2006, Vol. 168 Issue 28, p11 

    The article announces the plan of Akzo Nobel to float 20% to 30% of its combined pharmaceutical and veterinary medicines business under a previously announced initial public offering (IPO). Shareholders will vote on plans to split Akzo into two separately quoted companies. Organon BioSciences...

  • IPO of Organon BioSciences Imminent. van der Zanden, Tim // China Chemical Reporter;3/6/2007, Vol. 18 Issue 7, p10 

    The article focuses on an announcement made by Akzo Nobel NV regarding its plan of launching an initial public offering (IPO) for the firm Organon BioSciences. A listing of about 20 to 30 percent of Organon BioSciences' shares on Euronext Amsterdam was done by Akzo. According to Hans Wijers,...

  • Akzo Nobel will accelerate growth. Baker, John // ICIS Chemical Business;2/19/2007, Vol. 2 Issue 54, p5 

    The article reports on the plan of Akzo Nobel to accelerate its growth as a focused coatings and chemicals business. The firm confirmed that it will begin the spin-off of its Organon BioSciences unit by the end of March 2007. Akzo board member Leif Darner emphasized that the company has a clear...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics